MYC and lung adenocarcinoma: Omomyc, a dominant negative c-Myc, interferes with the ability of c-Myc/Max complexes to bind and activate their target genes.243 In a preclinical model of lung adenocarcinoma, Omomyc slowed tumor growth, and when combined with paclitaxel (PubChem CID: 36314), almost completely abrogated tumor growth.244 Due to its high anti-cancer potential and limited side effects, Omomyc is about to reach clinical trials for lung, breast and colorectal cancers.